Sign in
Active, not recruitingPhase 2

Sildenafil for Treatment of Urinary Incontinence in Patients With Spinal Cord Injuries

Key facts

Who runs it
The University of Texas Medical Branch, Galveston
Where
College Station and Galveston, United StatesSee the 2 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
24 people, planned
Started
7 Jul 2021
Expected to end
1 Dec 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Sildenafil Citrate
  • Placebo
Record updated
9 September 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Adults with spinal cord injury (SCI), 18-75 years of age, at the time of consent
  • Have urinary incontinence (UI), with at least 3 leakage episodes/week
  • Have urodynamics assessment on file with their provider in past 3 years. If no historical data on file, subject may complete prior to study visit 1
  • Willing and able to comply with study procedures
  • Willing and able to provide written informed consent

Who cannot take part

  • Use of systemic nitrates, anabolic steroids, corticosteroids, or long acting PDE5 inhibitors in the past 1 month
  • Use of short acting PDE5 inhibitors in the past 1 week
  • Atonic bladder or high detrusor and high pelvic floor muscle pressure based on previous cystometrogram (CMG) (on file with their provider) that would place subjects at risk for kidney injury
  • History of greater than 4 urinary tract infections per year
  • Significant heart, liver, kidney, pulmonary, blood, autoimmune or peripheral vascular disease
  • Active cancer
  • HIV, Hepatitis B, or Hepatitis C
  • Known allergic reaction to any agent under investigation or required by the protocol
  • Any medical condition that, in the opinion of the investigator, would place the subject at increased risk for participation
  • In phone prescreen, delighted or pleased with current quality of life due to urinary symptoms
  • Indwelling catheter
  • Multiple sclerosis
  • Systolic blood pressure <90 or >170, diastolic blood pressure <50 or >110 after repeated evaluation with proper cuff. This range is the acceptable range stated in the prescribing information for sildenafil (>90/50 and <170/110)
  • Use of alpha blockers, anticholinergic agents, bethanechol, or other UI treatment within the past 2 weeks ( 3 weeks for long acting muscarinic receptor antagonists)
  • Females who are pregnant or lactating

Where in United States

  • Texas A&M UniversityCollege Station, United States
  • University of Texas Medical BranchGalveston, United States

About the trial

What the trial wants to find out

The goal of this study is to determine whether administration of sildenafil will decrease urine leakage in patients with spinal cord injuries.

The 2 groups in the trial

  • Sildenafil 20mg TID then Placebo TIDTreatment being tested

    Subjects will be administered Sildenafil 20mg TID for 4 weeks. There will be a 2 week washout period then subjects will be administered Placebo (lactose) TID for 4 weeks.

    Treatment: Sildenafil Citrate and Placebo

  • Placebo TID then Sildenafil 20mg TIDTreatment being tested

    Subjects will be administered Placebo (lactose) TID for 4 week. There will be a 2 week washout period and then subjects will be administered Sildenafil 20mg TID for 4 weeks.

    Treatment: Sildenafil Citrate and Placebo

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
9 September 2026